Prosonix is developing a portfolio of enhanced respiratory medicines (mono and combination therapies) that could revolutionise the multi-billion dollar global market for inhaled therapies.

Its lead development programmes have the potential to offer distinct and high value benefits to patients, physicians, healthcare providers, and payors. They include:

• a drug-only version of fluticasone propionate (FP), a potent inhaled corticosteroid (ICS) monotherapy for
asthma in metered dose inhaler (MDI)

• a drug-only version of glycopyrrolate, a long acting muscarinic antagonist (LAMA) for chronic obstructive
pulmonary disorder (COPD) in MDI, and

Prosonix' unique proprietary DISCUS^® and UMAX^® particle engineering technologies generate ‘smart' respiratory drug particles that are specifically designed to target the optimum site of action in the lung, precisely and consistently, to gain maximum clinical effect.

By controlling particle size, shape and form (already demonstrated with ICS, LAMA, long acting beta agonists (LABA) and other inhaled drugs), Prosonix can develop superior drug formulations, offering more accurate dosing and enabling the use of simple, cost-effective MDI and dry powder inhaler (DPI) devices.

These ‘smart' medicines are anticipated to have important clinical advantages to patients over currently marketed products owing to their precise and predictable targeting to the site of action in the lung, such as:

• Improved dose consistency, eliminating variability

• Reduced dose with clinical comparability

• Maximised effectiveness of delivered dose

• Improved patient compliance

Targeting combination therapy, Prosonix can also generate novel and proprietary multi-component particles (MCP^TM) combining two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation. The MCP^TM are fully co-associated and have been shown to facilitate co-localisation of active pharmaceutical components at the site of action, which in turn offers the potential for enhanced synergistic clinical effect.

Prosonix intends to deliver the enormous potential of its technology through selecive high-profile partnerships with big pharma, while its approach has already been validated through multiple successful pharma collaborations.

Prosonix raised £11.4 million in June 2011 from experienced life sciences investors including Ventech, Gilde Healthcare Partners, Enterpreneurs Fund, Quest for Growth and Solon Ventures.